Bora Health, subsidiary of SunWay Biotech which focuses on pharmaceutical distribution and sales in Taiwan, has entered into a strategic collaboration with global pharmaceutical leader Dr. Reddy’s Laboratories. The partnership grants Bora Health the distribution rights in Taiwan of 4 products in the infection, central nervous system therapeutic areas and rare diseases.
This collaboration not only enhances hospital-facing portfolio of Bora Health but also aligns with Bora Group’s long-term strategy to expand its footprint in rare diseases and specialty pharma, furthering its mission to close critical gaps in Taiwan’s healthcare landscape.
Bobby Sheng, Chairman of SunWay Biotech, stated, “After careful evaluation on global geo complexities and Taiwan’s evolving pharmaceutical needs, we are proud to collaborate with Dr. Reddy’s to broaden access to high-quality generics and deepen our commitment to rare disease solutions. We look forward to becoming a vital partner to healthcare institutions and delivering greater impact to patients in need in Taiwan.”
Satheeshkumar Sriharan, Cluster Head, Greater China, at Dr. Reddy’s, attended the signing ceremony in person and commented, “We are excited to work with Bora Health. With their strong sales team in pharmaceuticals and reputable brand name, we are certain that both companies shall benefit from this partnership through diversified, effective treatment options to patients with limited access to critical therapies, in keeping with our purpose of Good Health Can’t Wait.”
Bora Health became part of the SunWay Biotech Co., the consumer healthcare arm of Bora Group following the November 2023 reverse acquisition. Bora Health primarily focuses on the distribution of finished products, including prescription drugs, OTC products, health food and skincare items. Bora Health has an extensive presence across major channels in Taiwan, including hospitals, clinics, pharmacies, and direct-to-consumer e-commerce platforms.
